Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | CASR | P41180 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11794365 | 0.86 | SLC2A1 (0.57) | SLC2A1CASRMEN1KMT2AALDH1A1 | |
| SCHEMBL5013630 | 0.82 | KDM4E (0.48) | BACE1BCHEALDH1A1CA2CTSD | |
| SCHEMBL23365972 | 0.82 | BACE1 (0.41) | BACE1CASRMEN1KMT2ABCHE | |
| SCHEMBL13181716 | 0.81 | BCHE (0.44) | BACE1CASRMEN1KMT2ABCHE | |
| SCHEMBL12778461 | 0.79 | TSHR (0.34) | SLC2A1MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL12956598 | 0.79 | BCHE (0.56) | BACE1CASRMEN1KMT2ABCHE | |
| SCHEMBL19523060 | 0.79 | BCHE (0.49) | BACE1BCHEALDH1A1CYP2D6CA2 | |
| SCHEMBL20631430 | 0.78 | SLC2A1 (0.51) | SLC2A1MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL14229981 | 0.78 | SLC2A1 (0.51) | SLC2A1CASRMEN1KMT2AALDH1A1 | |
| SCHEMBL11983546 | 0.78 | ALDH1A1 (0.63) | SLC2A1ALDH1A1CYP2D6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
| EP-3086815-B1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2022-02-09 | — | — | EP | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-10012650-B2 | Assays for BTK inhibitors | MERCK PATENT GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | SLC2A1 848/4885BACE1 3872/4885CASR 3384/4885 |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | SLC2A1 4869/4885BACE1 4385/4885CASR 3125/4885 |
| US-20160169894-A1 | ASSAYS FOR BTK INHIBITORS | BTK, SYK, LYN | SLC2A1 4872/4885BACE1 3594/4885CASR 2007/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | SLC2A1 2360/4885BACE1 3929/4885CASR 4688/4885 |
| US-10012650-B2 | Assays for BTK inhibitors | BTK, SYK, LYN | SLC2A1 4872/4885BACE1 3594/4885CASR 2007/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | SLC2A1 848/4885BACE1 3872/4885CASR 3384/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | SLC2A1 4869/4885BACE1 4385/4885CASR 3125/4885 |
| US-20170029490-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | SLC2A1 848/4885BACE1 3872/4885CASR 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.